10x Genomics (TXG) Consolidated Net Income (2018 - 2026)

10x Genomics has disclosed Consolidated Net Income across 9 years of filings, most recently posting -$13.5 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at -$13.5 million, up 60.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$22.7 million (up 85.57% YoY), and the FY2025 annual result was -$43.5 million, up 76.16% from the prior year.
• Consolidated Net Income came in at -$13.5 million for Q1 2026 at 10x Genomics, up from -$16.3 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of $34.5 million in Q2 2025 to a low of -$93.0 million in Q3 2023.
• The 5-year median for Consolidated Net Income is -$41.9 million (2022), against an average of -$38.9 million.
• Across the five-year window, Consolidated Net Income sank 483.22% in 2022 and surged 191.14% in 2025, its largest moves.
• 10x Genomics' Consolidated Net Income stood at -$17.2 million in 2022, then tumbled by 184.36% to -$49.0 million in 2023, then dropped by 0.16% to -$49.0 million in 2024, then surged by 66.85% to -$16.3 million in 2025, then rose by 17.12% to -$13.5 million in 2026.
• The last three Consolidated Net Income figures came in at -$13.5 million (Q1 2026), -$16.3 million (Q4 2025), and -$27.5 million (Q3 2025), per Business Quant data.